The Food and Drug Administration meets this week to consider a much-debated treatment for Lou Gehrig’s disease. The deadly neurological disease has few treatment options. NurOwn, a stem cell therapy, is at the center of a yearslong lobbying campaign by patients seeking access to experimental medicines. But the FDA has repeatedly rebuffed drugmaker Brainstorm. The agency says the company's only study failed to show a benefit for patients. The review is the starkest test yet of FDA's commitment to “regulatory flexibility” to help patients with rare, deadly conditions. Advocates see reasons for optimism. The FDA has approved two new treatments for ALS in the past year after intense lobbying by patients.
“FDA is the 800-pound gorilla here, and if they’re convinced that the drug doesn’t work, it’s very hard to change their minds,” a former FDA official said.
FDA skeptical of experimental ALS treatment pushed by patient advocates | iNFOnews infotel.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from infotel.ca Daily Mail and Mail on Sunday newspapers.
The FDA is meeting this week to consider NurOwn, a much-debated treatment for Lou Gehrig’s disease. The agency says the treatment hasn't been shown to work.